about
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicityIntensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion.Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase familyGlutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells.Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri InstHigh resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesisCombination chemotherapy with nedaplatin and cyclophosphamide in human ovarian cancer model.
P2860
Q24547477-FB02D3E3-3E0A-4E3A-A961-97FEAA0A1411Q33376938-2874F9BD-B72C-4F59-A26A-BBDC15129509Q33487862-9711A477-832C-435E-A283-8DCBF2242006Q33883716-226B0F76-545F-48FE-A4C5-DC798667AE13Q33948137-4CE7C104-3AA0-4860-A727-6BC48A7DC560Q35994616-5ADDB4E6-FF3E-4806-8A59-9762F19F72CFQ36116265-AB481E7D-B0DF-4562-92B4-34E0137F07A5Q36422416-ACD141BF-5287-4EFF-AAD0-C308F781DA2FQ36430931-9E0F1E2F-2A5D-4AF1-B670-AD463F70A0EBQ36566743-163A0B8B-9035-4591-9AA7-D8016FFCA6CBQ36694220-21191231-4C59-4C18-8D86-2C437981B921Q36936167-2BB8D7E7-3F57-4A2F-B369-97B82D106530Q55286901-68797D55-C9E2-4610-8E3C-CE12E572AC6E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy of ovarian cancer.
@en
type
label
Chemotherapy of ovarian cancer.
@en
prefLabel
Chemotherapy of ovarian cancer.
@en
P1433
P1476
Chemotherapy of ovarian cancer.
@en
P2093
P304
P577
1991-06-01T00:00:00Z